Drug Profile
GLS 5700
Alternative Names: GLS5700; INO-4600Latest Information Update: 06 Sep 2023
Price :
$50
*
At a glance
- Originator GeneOne Life Science; Inovio Pharmaceuticals
- Class DNA vaccines; Monoclonal antibodies; Viral vaccines; Zika virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Zika virus infection
Highest Development Phases
- Phase I Zika virus infection
Most Recent Events
- 06 Sep 2023 Phase I development for Zika-virus-infection(In the elderly, Prevention, In adults) is ongoing in the US, Canada and Puerto Rico (GeneOne Life Science pipeline, September 2023)
- 28 Apr 2022 No recent reports of development identified for phase-I development in Zika-virus-infection(In the elderly, Prevention, In adults) in Puerto Rico (Intradermal)
- 28 Apr 2022 No recent reports of development identified for phase-I development in Zika-virus-infection(Prevention) in Canada (Intradermal)